Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Submits First PMA Module for BRACAnalysis CDx

NEW YORK (GenomeWeb News) ─ Myriad Genetics has submitted to the US Food and Drug Administration the first module of its premarket approval application for BRACAnalysis as a companion test for AstraZeneca's breast cancer PARP inhibitor olaparib.

The test is being used in two Phase III trials to pick out ovarian cancer patients who harbor BRCA mutations and as such are thought to be best responders to olaparib. Myriad filed an investigational device exemption application with the FDA less than a year ago to enable it to use BRACAnalysis as part of these studies. According to Myriad, the company has submitted the first of four PMA modules to date.

"BRACAnalysis is one of the first laboratory developed tests submitted for FDA premarket approval," Mark Capone, president of Myriad Genetics Laboratories, said in a statement.

Myriad and AstraZeneca's partnership to develop BRACAnalysis as a companion test for olaparib began in 2007. Last year, the firms expanded their collaboration, and Myriad announced it would build a new laboratory at its Salt Lake City headquarters to develop companion diagnostics in line with FDA regulations.

Before olaparib makes its way through the US regulatory process, the drug may first come to market in Europe. The European Medicines Agency accepted AstraZeneca's marketing application for olaparib last September, and the firm expects to hear from regulators there in 2015. A positive review of the drug would necessitate the simultaneous market launch of olaparib and the BRACAnalysis companion test.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.